Omnicell, Inc. (NASDAQ:OMCL) Receives $41.33 Consensus Price Target from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned an average rating of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $41.33.

A number of research firms recently commented on OMCL. JPMorgan Chase & Co. upped their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Benchmark reaffirmed a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Wells Fargo & Company raised their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Bank of America boosted their price objective on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd.

Omnicell Stock Down 2.7 %

OMCL opened at $41.43 on Tuesday. The company has a fifty day moving average of $43.21 and a two-hundred day moving average of $34.15. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $45.84. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -90.07, a PEG ratio of 47.35 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. On average, research analysts expect that Omnicell will post 0.64 earnings per share for the current year.

Institutional Trading of Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning lifted its holdings in shares of Omnicell by 23.1% in the 3rd quarter. Creative Planning now owns 11,667 shares of the company’s stock valued at $509,000 after buying an additional 2,188 shares during the period. Diversified Trust Co raised its position in shares of Omnicell by 43.0% during the 3rd quarter. Diversified Trust Co now owns 21,966 shares of the company’s stock worth $958,000 after purchasing an additional 6,602 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Omnicell by 67.3% in the 3rd quarter. SG Americas Securities LLC now owns 25,157 shares of the company’s stock valued at $1,097,000 after purchasing an additional 10,116 shares in the last quarter. Finally, Algert Global LLC boosted its position in Omnicell by 9.8% during the second quarter. Algert Global LLC now owns 51,942 shares of the company’s stock worth $1,406,000 after acquiring an additional 4,617 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.